Disease Progression in Multiple System Atrophy: The <scp>ASPIRE</scp> Multi‐Modal Biomarker Study

20254 citationsJournal Articlehybrid Open Access

Authors

Margherita Fabbri · Université Toulouse III - Paul Sabatier

Natalia del Campo · Inserm

Wassilios G. Meissner · Centre National de la Recherche Scientifique

Vanessa Rousseau · Université Fédérale de Toulouse Midi-Pyrénées

Agnès Sommet · Université Fédérale de Toulouse Midi-Pyrénées

Pierre Payoux · Université Toulouse III - Paul Sabatier

Pierre Gantet

Abstract

Neuroimaging changes occur within 6 months in early MSA. High plasma NfL levels are linked to increased mortality and dropout risk. Longitudinal biomarker assessments provide valuable insights into disease progression. ANN NEUROL 2026;99:96-113.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Botulinum Toxin and Related Neurological Disorders Advanced Neuroimaging Techniques and Applications

Publication Details

Published in: Annals of Neurology

Volume 99, Issue 1, pp. 96-113

DOI: 10.1002/ana.70028

Field-Weighted Citation Impact: 5.56

Command Palette

Disease Progression in Multiple System Atrophy: The <scp>ASPIRE</scp> Multi‐Modal Biomarker Study

Authors

Abstract

Topics & Keywords

Publication Details